ONTOLOGY REPORT - ANNOTATIONS
| Term: | abnormal gland morphology |
|
| Accession: | MP:0002163
|
browse the term
|
| Definition: | any structural anomaly of an organ that functions as a secretory or excretory organ |
| Synonyms: | exact_synonym: | abnormal glands; abnormal glands morphology; gland abnormalities; glands: dysmorphology; glandular dysplasia |
| | alt_id: | MP:0000594 |
| | xref: | MGI:2173623 |
|
|
abnormal adrenal gland morphology
|
| G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
|
|
IAGP |
7 |
113,043,365 |
113,049,779 |
RGD:727991 |
RGD |
| Q |
Sradr1 |
Stress Responsive Adrenal Weight QTL 1 |
|
|
IED |
1 |
28,716,493 |
124,749,065 |
RGD:1598980 |
RGD |
| Q |
Sradr2 |
Stress Responsive Adrenal Weight QTL 2 |
|
|
IED |
2 |
133,459,258 |
157,917,105 |
RGD:1598980 |
RGD |
| Q |
Sradr3 |
Stress Responsive Adrenal Weight QTL 3 |
|
|
IED |
4 |
56,690,161 |
101,690,161 |
RGD:1598980 |
RGD |
| Q |
Sradr4 |
Stress Responsive Adrenal Weight QTL 4 |
|
|
IED |
4 |
132,846,974 |
177,846,974 |
RGD:1598980 |
RGD |
| Q |
Sradr5 |
Stress Responsive Adrenal Weight QTL 5 |
|
|
IED |
7 |
47,145,687 |
114,883,369 |
RGD:1598980 |
RGD |
| Q |
Sradr6 |
Stress Responsive Adrenal Weight QTL 6 |
|
|
IED |
18 |
12,406,975 |
62,106,220 |
RGD:1598980 |
RGD |
abnormal pancreas morphology
|
| S |
SD/Rij |
|
|
|
IED |
|
|
|
RGD:628479 |
RGD |
| S |
SDT/CrljJcl |
|
|
|
IED |
|
|
|
RGD:628479 |
RGD |
| S |
WBN |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
abnormal pancreatic islet morphology
|
| Q |
Iddm21 |
Insulin dependent diabetes mellitus QTL 21 |
|
|
IAGP |
|
|
|
RGD:1547853 |
RGD |
| Q |
Iddm22 |
Insulin dependent diabetes mellitus QTL 22 |
|
|
IAGP |
|
|
|
RGD:1547853 |
RGD |
| Q |
Iddm23 |
Insulin dependent diabetes mellitus QTL 23 |
|
|
IAGP |
|
|
|
RGD:1547853 |
RGD |
| Q |
Niddm4 |
Non-insulin dependent diabetes mellitus QTL 4 |
|
|
QTM |
1 |
212,121,314 |
240,980,321 |
RGD:61083 |
RGD |
| Q |
Pancm1 |
Pancreatic morphology QTL 1 |
|
|
QTM |
1 |
186,391,887 |
220,639,539 |
RGD:61083 |
RGD |
| S |
LEW.1AR1-iddm/Ztm |
|
|
|
IAGP |
|
|
|
RGD:1547853 |
RGD |
abnormal prostate gland epithelium morphology
|
| S |
NBL |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
abnormal prostate gland morphology
|
| Q |
Prcr1 |
Prostate cancer resistance QTL 1 |
|
|
IAGP |
2 |
73,374,972 |
163,154,358 |
RGD:1358944 |
RGD |
| Q |
Prcr2 |
Prostate cancer resistance QTL 2 |
|
|
IAGP |
|
|
|
RGD:1358944 |
RGD |
| Q |
Prcs1 |
Prostate cancer susceptibility QTL 1 |
|
|
IAGP |
19 |
16,245,310 |
36,472,155 |
RGD:1358944 |
RGD |
| Q |
Prcs2 |
Prostate cancer susceptibility QTL 2 |
|
|
IAGP |
20 |
4,740,609 |
18,411,969 |
RGD:1358944 |
RGD |
abnormal Sertoli cell morphology
|
| S |
KH |
|
|
|
IED |
|
|
|
RGD:2301322 |
RGD |
cryptorchism
|
| S |
KH |
|
|
|
IED |
|
|
|
RGD:2301322 |
RGD |
| S |
LE/Orl |
Long-Evans/Cryptorchid |
|
Model |
IED |
|
|
|
RGD:2301308 |
RGD |
decreased pancreas weight
|
| Q |
Gluco61 |
Glucose level QTL 61 |
|
|
IED |
4 |
34,206,019 |
38,029,988 |
RGD:2326163 |
RGD |
| Q |
Gluco62 |
Glucose level QTL 62 |
|
|
IED |
11 |
56,625,258 |
67,465,962 |
RGD:2326163 |
RGD |
| Q |
Gluco63 |
Glucose level QTL 63 |
|
|
IED |
13 |
84,280,242 |
111,154,910 |
RGD:2326163 |
RGD |
| Q |
Pancm4 |
Pancreatic morphology QTL 4 |
|
|
IAGP |
4 |
23,537,363 |
74,625,985 |
RGD:1626640 |
RGD |
decreased pancreatic beta cell mass
|
| Q |
Pancm2 |
Pancreatic morphology QTL 2 |
|
|
IED |
10 |
81,350,126 |
126,350,126 |
RGD:4889455 |
RGD |
| S |
GK/Ox |
|
|
|
IED |
|
|
|
RGD:4889455 |
RGD |
| S |
SD-Tg(Ins2-IAPP)Soel |
|
|
|
IED |
|
|
|
RGD:2313576 |
RGD |
decreased pancreatic beta cell number
|
| S |
SD-Tg(Ins2-IAPP)Soel |
|
|
|
IED |
|
|
|
RGD:2313576 |
RGD |
| S |
SDT/CrljJcl |
|
|
|
TAS |
|
|
|
RGD:2298688 |
RGD |
decreased testis weight
|
| Q |
Teswt1 |
Testicular weight QTL 1 |
|
|
IED |
7 |
85,089,895 |
100,273,797 |
RGD:1625009 |
RGD |
| Q |
Teswt2 |
Testicular weight QTL 2 |
|
|
IED |
1 |
202,790,380 |
247,790,380 |
RGD:1625009 |
RGD |
enlarged adrenal glands
|
| S |
WKY/NHsd |
|
|
|
IED |
|
|
|
RGD:1598980 |
RGD |
enlarged testis
|
| G |
Fmr1 |
fragile X mental retardation 1 |
|
|
IEA |
X |
154,756,031 |
154,793,782 |
RGD:704404 |
RGD |
increased pancreas weight
|
| Q |
Pancm3 |
Pancreatic morphology QTL 3 |
|
|
IED |
20 |
18,411,845 |
48,055,886 |
RGD:2326163 |
RGD |
| S |
CDS-Chr 4CDR/Ygl |
|
|
|
IED |
|
|
|
RGD:2326163 |
RGD |
mammary gland alveolar hyperplasia
|
| S |
ACI/SegHsd |
|
|
|
IED |
|
|
|
RGD:1358963 |
RGD |
| S |
COP/CrCrl |
|
|
|
IED |
|
|
|
RGD:1358963 |
RGD |
mammary gland hypoplasia
|
| S |
WTC-swh/Kyo |
|
|
|
IED |
|
|
|
RGD:2304219 |
RGD |
pancreas fibrosis
|
| S |
F344.SDT-(D3Wox9-D3Arb20)/Kbe |
|
|
|
IED |
3 |
47,722,501 |
47,722,628 |
RGD:2298688 |
RGD |
pancreatic islet hyperplasia
|
| G |
Gcgr |
glucagon receptor |
|
|
IEA |
10 |
109,921,411 |
109,929,577 |
RGD:704404 |
RGD |
pituitary gland hyperplasia
|
| Q |
Edpm1 |
Estrogen-dependent pituitary mass QTL 1 |
|
|
QTM |
2 |
42,866,226 |
87,866,226 |
RGD:61074 |
RGD |
| Q |
Edpm10 |
Estrogen-dependent pituitary mass QTL 10 |
|
|
QTM |
|
|
|
RGD:61074 |
RGD |
| Q |
Edpm11 |
Estrogen-dependent pituitary mass QTL 11 |
|
|
QTM |
9 |
1 |
39,963,583 |
RGD:629550 |
RGD |
| Q |
Edpm12 |
Estrogen-dependent pituitary mass QTL 12 |
|
|
QTM |
X |
23,620,000 |
68,620,000 |
RGD:629550 |
RGD |
| Q |
Edpm2 |
Estrogen-dependent pituitary mass QTL 2 |
|
|
QTM |
2 |
77,630,629 |
210,636,169 |
RGD:61074 |
RGD |
| Q |
Edpm3 |
Estrogen-dependent pituitary mass QTL 3 |
|
|
QTM |
3 |
50,522,717 |
88,648,420 |
RGD:61074 |
RGD |
| Q |
Edpm5 |
Estrogen-dependent pituitary mass QTL 5 |
|
|
QTM |
5 |
71,814,715 |
109,163,425 |
RGD:61074 |
RGD |
| Q |
Edpm9 |
Estrogen-dependent pituitary mass QTL 9 |
|
|
QTM |
|
|
|
RGD:61074 |
RGD |
| Q |
Ept1 |
Estrogen-induced pituitary tumorigenesis QTL 1 |
|
|
IAGP |
6 |
1 |
8,184,962 |
RGD:1334449 |
RGD |
| Q |
Ept10 |
Estrogen-induced pituitary tumorigenesis QTL 10 |
|
|
IAGP |
1 |
197,770,157 |
250,119,666 |
RGD:1334449 |
RGD |
| Q |
Ept13 |
Estrogen-induced pituitary tumorigenesis QTL 13 |
|
|
IAGP |
1 |
23,633,441 |
77,148,378 |
RGD:1334449 |
RGD |
| Q |
Ept15 |
Estrogen-induced pituitary tumorigenesis QTL 15 |
|
Induced |
IED |
6 |
1 |
8,184,962 |
RGD:2292503 |
RGD |
| Q |
Ept16 |
Estrogen-induced pituitary tumorigenesis QTL 16 |
|
Induced |
IED |
3 |
44,551,542 |
110,215,186 |
RGD:2292503 |
RGD |
| Q |
Ept17 |
Estrogen-induced pituitary tumorigenesis QTL 17 |
|
Induced |
IED |
3 |
6,373,454 |
22,341,164 |
RGD:2292503 |
RGD |
| Q |
Ept18 |
Estrogen-induced pituitary tumorigenesis QTL 18 |
|
Induced |
IED |
10 |
77,092,169 |
100,633,512 |
RGD:2292503 |
RGD |
| Q |
Ept2 |
Estrogen-induced pituitary tumorigenesis QTL 2 |
|
|
IAGP |
3 |
44,551,542 |
110,215,186 |
RGD:1334449 |
RGD |
| Q |
Ept5 |
Estrogen-induced pituitary tumorigenesis QTL 5 |
|
|
IED |
4 |
82,700,691 |
182,307,104 |
RGD:1642526 |
RGD |
| Q |
Ept6 |
Estrogen-induced pituitary tumorigenesis QTL 6 |
|
|
IAGP |
3 |
6,373,454 |
22,341,164 |
RGD:1334449 |
RGD |
| Q |
Ept7 |
Estrogen-induced pituitary tumorigenesis QTL 7 |
|
|
IED |
7 |
66,201,980 |
107,428,439 |
RGD:1642526 |
RGD |
| Q |
Ept9 |
Estrogen-induced pituitary tumorigenesis QTL 9 |
|
|
IAGP |
10 |
77,092,169 |
100,633,512 |
RGD:1334449 |
RGD |
| S |
ACI/SegHsd |
|
|
Induced |
IED |
|
|
|
RGD:1642526 |
RGD |
| S |
F344/NHsd |
F344/NHsd |
|
|
QTM |
|
|
|
RGD:61074 |
RGD |
pituitary gland hypoplasia
|
| S |
ACI.COP-(D10Mgh8-D10Rat4)/Shul |
|
|
Induced |
IED |
10 |
53,781,126 |
107,033,716 |
RGD:2292503 |
RGD |
| S |
ACI.COP-(D3Rat130-D3Rat114)/Shul |
|
|
Induced |
IED |
3 |
44,551,252 |
149,496,698 |
RGD:2292503 |
RGD |
| S |
ACI.COP-(D6Rat80-D6Rat146)/Shul |
|
|
Induced |
IED |
6 |
16,302,145 |
16,302,283 |
RGD:2292503 |
RGD |
prostate gland epithelial hyperplasia
|
| S |
NBL |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
prostate gland hyperplasia
|
| G |
Kdr |
kinase insert domain receptor |
|
|
IEP |
|
|
|
RGD:2292079 |
RGD |
| Q |
Prcs1 |
Prostate cancer susceptibility QTL 1 |
|
|
IAGP |
19 |
16,245,310 |
36,472,155 |
RGD:1358944 |
RGD |
| Q |
Prcs2 |
Prostate cancer susceptibility QTL 2 |
|
|
IAGP |
20 |
4,740,609 |
18,411,969 |
RGD:1358944 |
RGD |
| S |
AXC |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
| S |
COP |
|
|
|
TAS |
|
|
|
RGD:1004 |
RGD |
prostate gland hypoplasia
|
| Q |
Prcr1 |
Prostate cancer resistance QTL 1 |
|
|
IAGP |
2 |
73,374,972 |
163,154,358 |
RGD:1358944 |
RGD |
| Q |
Prcr2 |
Prostate cancer resistance QTL 2 |
|
|
IAGP |
|
|
|
RGD:1358944 |
RGD |
small adrenal glands
|
| Q |
Gmadr1 |
Adrenal mass QTL 1 |
|
|
IAGP |
19 |
25,548,711 |
39,854,409 |
RGD:1302889 |
RGD |
small seminal vesicle
|
| Q |
Inf1 |
Infertility severity QTL 1 |
|
|
IED |
8 |
26,358,063 |
71,358,063 |
RGD:631224 |
RGD |
testis hypoplasia
|
| G |
Fgf9 |
fibroblast growth factor 9 |
|
|
IEA |
15 |
37,115,068 |
37,155,652 |
RGD:704404 |
RGD |
| S |
KH |
|
|
|
IED |
|
|
|
RGD:2301322 |
RGD |
Term paths to the root
|